Corient Private Wealth LLC Decreases Stake in The Cooper Companies, Inc. $COO

Corient Private Wealth LLC cut its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 14.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,318 shares of the medical device company’s stock after selling 8,099 shares during the quarter. Corient Private Wealth LLC’s holdings in Cooper Companies were worth $3,509,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sustainable Growth Advisers LP purchased a new stake in shares of Cooper Companies during the 2nd quarter valued at approximately $240,881,000. Ameriprise Financial Inc. raised its holdings in Cooper Companies by 98.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after acquiring an additional 1,683,561 shares during the period. Franklin Resources Inc. lifted its position in shares of Cooper Companies by 7,723.3% during the second quarter. Franklin Resources Inc. now owns 1,569,512 shares of the medical device company’s stock worth $111,686,000 after acquiring an additional 1,549,450 shares in the last quarter. Findlay Park Partners LLP boosted its holdings in shares of Cooper Companies by 312.5% in the second quarter. Findlay Park Partners LLP now owns 1,815,900 shares of the medical device company’s stock worth $129,219,000 after acquiring an additional 1,375,657 shares during the period. Finally, Soundwatch Capital LLC bought a new position in shares of Cooper Companies in the second quarter worth $607,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $82.75 on Monday. The company’s fifty day moving average price is $74.70 and its 200-day moving average price is $72.06. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The firm has a market capitalization of $16.22 billion, a price-to-earnings ratio of 44.02, a PEG ratio of 2.36 and a beta of 1.05. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $100.24.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies announced that its board has initiated a stock repurchase plan on Wednesday, September 17th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at Cooper Companies

In other news, Director Maria Rivas bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was bought at an average price of $82.13 per share, for a total transaction of $82,130.00. Following the transaction, the director directly owned 11,141 shares of the company’s stock, valued at $915,010.33. This represents a 9.86% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were acquired at an average cost of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the purchase, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This represents a 34.62% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 16,230 shares of company stock valued at $1,291,233. 1.98% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Barclays reissued an “overweight” rating and set a $91.00 price objective on shares of Cooper Companies in a report on Monday, December 8th. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the company a “buy” rating in a research report on Friday, December 5th. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target (up from $94.00) on shares of Cooper Companies in a report on Friday, December 5th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $94.00 target price (up previously from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Cooper Companies has an average rating of “Moderate Buy” and a consensus price target of $90.15.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.